Want to create an interactive transcript for this episode?
Podcast: Pharmacy Podcast Network
Episode: Challenges in Treatment of Desmoid Tumors and Managed Care Solutions | PTCE Pharmacy Connect
Description: PTCE aims to present the most updated information available. In November 2023, the US FDA approved the first orally administered, γ-secretase inhibitor therapy, nirogacestat (Ogsivo), for the treatment of adult patients with desmoid tumors. Please refer to the prescribing information for additional information.
Pharmacy Times Continuing Education (PTCE) provides industry leading pharmacy CE to retail, oncology, managed care, specialty, and health-systems pharmacists. They use multiple deliverables in the live, virtual, on-demand, and print formats created by in-house pharmacists to deliver tailored multi-specialty education.
Challenges in Treatment of Desmoid Tumors and Managed Care Solutions
Â
...